Fludarabine
Head and Neck Squamous Cell Carcinoma
Beijing BiotechSmall moleculePhase 1/2Active
CCC
49/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 44/ 100
- Competitive Position
- 65/ 100
Competitive context
249 Active assets in the Head and Neck Squamous Cell Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CIS-DIAMMINEDICHLOROPLATINUM II Akeso | Phase 3 | BB |
Carboplatin Akeso | Phase 4 | BB |
Irinotecan Neonc Technologies, Inc. | Phase 2 | BB |
Tisotumab Vedotin Seagen, a wholly owned subsidiary of Pfizer | Phase 2 | BB |
Capecitabine Merck Sharp & Dohme LLC | Phase 2 | BB |
View all 50 →
Same molecule, other indications
Fludarabine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →